Overview

The Gene Technology Act 2000, enacted by the Parliament of Australia, was introduced to address the need for a regulatory framework governing the use, handling, and release of genetically modified organisms. The Act aims to protect human health and the environment while allowing for the safe application of gene technology. The Gene Technology Regulator is responsible for assessing applications related to gene technology activities, including clinical trials with genetically modified organisms. In May 2021, the Regulator invited public comment on a proposed clinical trial by The Westmead Institute for Medical Research. This trial seeks to evaluate the use of genetically modified probiotic E.coli to reduce antibiotic resistance in the gastrointestinal tract of up to 100 participants over a five-year period at Westmead Hospital. The Regulator has prepared a Risk Assessment and Risk Management Plan (RARMP) for this application and is seeking submissions on issues relating to the protection of human health and safety and the environment before making a decision on whether to issue the licence. Submissions should reference DIR 183 and be submitted by 15 June 2021.

Scope and Application

The Gene Technology Act 2000, as amended by C2021G00330, governs the application submitted by The Westmead Institute for Medical Research for a clinical trial involving genetically modified E.coli. This Act applies to entities and individuals intending to conduct or undertake gene technology activities within Australia, including research institutions and medical bodies. The Act regulates the handling, use, and release of genetically modified organisms (GMOs) to safeguard human health and the environment. The clinical trial in question, proposed to occur at Westmead Hospital, involves up to 100 participants over five years and aims to reduce antibiotic resistance through the use of modified E.coli. The geographic reach of this legislation is national, with the Gene Technology Regulator overseeing compliance and risk management across Australia. Exclusions or exemptions under this Act are minimal, as most gene technology activities require assessment and licensing. Subordinate instruments may further define specific operational details or conditions for such trials. Public submissions on the Risk Assessment and Risk Management Plan are encouraged to ensure comprehensive scrutiny before any licence is issued.

Key Provisions

The primary sections of the legislation (C2021G00330) pertain to the assessment of an application by The Westmead Institute for Medical Research to conduct a clinical trial using genetically modified probiotic E.coli to combat antibiotic resistance in the gastro-intestinal tract of up to 100 participants over five years at Westmead Hospital. The Office of the Gene Technology Regulator is responsible for evaluating this application, and it has prepared a Risk Assessment and Risk Management Plan (RARMP) to aid in this process (section 1). The Regulator is inviting written submissions on issues related to human health and safety and the environment before making a decision on whether to grant the licence (section 2). Submissions must reference DIR 183 and be submitted by 15 June 2021 (section 3). The obligations imposed on The Westmead Institute for Medical Research, as the applicant, include providing detailed information about the proposed clinical trial, including the genetically modified E.coli, the trial's methodology, and its potential impact on human health and the environment. The Institute must also ensure compliance with the RARMP and address any concerns raised during the assessment process. Additionally, the Institute must maintain records of the trial and report any incidents or adverse effects to the Regulator (section 4). The legislation also outlines potential consequences for non-compliance or breaches of the terms set forth in the legislation. Offences under this Act may include conducting the trial without the necessary licence, failing to adhere to the RARMP, or not reporting incidents as required. Civil penalties may apply for breaches, with fines up to a specified maximum amount. In severe cases, criminal penalties, including imprisonment, may be imposed. These provisions are intended to ensure the safety and integrity of the clinical trial and protect both human health and the environment (section 5).